Salivary Analysis Based on Surface Enhanced Raman Scattering Sensors Distinguishes Early and Advanced Gastric Cancer Patients from Healthy Persons

Development of new methods to screen early gastric cancer patients has great clinical requirement. Ten amino acids in human saliva are identified as small metabolite biomarkers to distinguish early gastric cancer patients and advanced gastric cancer patients from healthy persons by using high performance liquid chromatography-mass spectrometry (HPLC-MS). Then, surface enhanced Raman scattering (SERS) sensors based on graphene oxide nanoscrolls wrapped with gold nanoparticles are developed to detect ten amino acids biomarkers in saliva. The distinctive graphene oxide nanoscrolls wrapped with gold nanoparticles are facilely prepared via ultrasonication without any organic stabilizer, and endow the SERS sensors with excellent uniformity, stability and SERS activity to adsorb and detect the biomarkers with 10(8) enhancement coefficient. The SERS sensors were confirmed to be feasible for distinguishing early gastric cancer patients and advanced gastric cancer patients from healthy persons by simulation samples and 220 clinical saliva samples with excellent performance (specificity >87.7% and sensitivity >80%). This non-invasive, cheap, fast and reliable salivary analysis method based on the SERS sensors provides a new strategy to screen out early gastric cancer patients and advanced gastric cancer patients from population, and owns clinical translational prospects.